## Ingrid E Wertz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9846962/publications.pdf

Version: 2024-02-01

1040056 1281871 1,204 12 9 11 citations h-index g-index papers 13 13 13 2675 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature, 2011, 471, 110-114.	27.8	682
2	From Discovery to Bedside: Targeting the Ubiquitin System. Cell Chemical Biology, 2019, 26, 156-177.	5.2	113
3	Activityâ€based probes for the ubiquitin conjugation–deconjugation machinery: new chemistries, new tools, and new insights. FEBS Journal, 2017, 284, 1555-1576.	4.7	109
4	The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. ELife, $2016, 5, .$	6.0	100
5	Molecular Understanding of USP7 Substrate Recognition and C-Terminal Activation. Structure, 2016, 24, 1335-1345.	3.3	67
6	Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics. Trends in Pharmacological Sciences, 2014, 35, 187-207.	8.7	40
7	Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms. Drug Discovery Today: Technologies, 2019, 31, 109-123.	4.0	40
8	Activityâ€based probes for the multicatalytic proteasome. FEBS Journal, 2017, 284, 1540-1554.	4.7	25
9	Antibody toolkit reveals N-terminally ubiquitinated substrates of UBE2W. Nature Communications, 2021, 12, 4608.	12.8	14
10	Rapid, semi-automated protein terminal characterization using ISDetect. Nature Biotechnology, 2016, 34, 811-813.	17.5	7
11	Targeted protein degradation: from small molecules to complex organellesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1510, 79-99.	3.8	5
12	Editorial overview: Hot targets and new modalities. Current Opinion in Chemical Biology, 2021, 62, A1-A3.	6.1	0